Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review

Published:2023-09-01 Issue:11 Volume:79 Page:1443-1452
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Arabloo Jalal,Azari Samad,Gorji Hasan Abolghasem,Rezapour Aziz,Alipour Vahid,Ehsanzadeh ‬Seyed Jafar

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-023-03557-6.pdf

Reference28 articles.

1. Delea TE, Sharma A, Grossman A et al (2019) Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ 22(2):117–130

2. Huang J, Pang WS, Lok V et al (2022) Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol 15(1):57

3. ACS About Hodgkin Lymphoma (2022) [Internet]

4. [cited 2022 Aug 9]. American Cancer Society. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8649.00.pdf

5. Huntington SF, Von Keudell GR, Davidoff AJ et al (2018) Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. J Clin Oncol 36(15)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance;Biomedicines;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP